{"transactions":[{"id":917306,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Chemistry Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-05T21:14:15.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":230000,"derivative":{"exercise_price":2.3,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001825005-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000182500526000002/primarydocument.xml","form_type":"4"}},{"id":1189482,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Chemistry Officer"}}],"security":"Common Stock","published_at":"2025-03-27T20:40:54.000Z","date":"2025-03-25","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.6925,"value":69250.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported total includes 2,500 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c)."}],"balance_after":480123,"source":{"system":"sec-edgar","filing":"0001562180-25-002779","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002779/primarydocument.xml","form_type":"4"}},{"id":1281397,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Chemistry Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-05T21:32:03.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":175000,"derivative":{"exercise_price":1.11,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001562180-25-000957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025000957/primarydocument.xml","form_type":"4"}},{"id":1321453,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Chemistry Officer"}}],"security":"Common Stock","published_at":"2024-12-26T12:49:38.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":1.3667,"value":82002.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":377623,"source":{"system":"sec-edgar","filing":"0001562180-24-008565","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218024008565/primarydocument.xml","form_type":"4"}},{"id":1321452,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Chemistry Officer"}}],"security":"Common Stock","published_at":"2024-12-26T12:49:38.000Z","date":"2024-12-20","kind":"purchase","planned":false,"acquired":true,"shares":3075,"price":1.15,"value":3536.25,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported total includes 10,106 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c)."}],"balance_after":317623,"source":{"system":"sec-edgar","filing":"0001562180-24-008565","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218024008565/primarydocument.xml","form_type":"4"}},{"id":1602264,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Chemistry Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-04T23:05:19.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.59,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001562180-24-002136","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218024002136/primarydocument.xml","form_type":"4"}},{"id":2024320,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-09T21:08:38.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":135000,"derivative":{"exercise_price":7.2,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001562180-23-001169","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218023001169/primarydocument.xml","form_type":"4"}},{"id":2307083,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-04-04T21:08:54.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":36062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":50397,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":36062},"source":{"system":"sec-edgar","filing":"0001209191-22-022524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919122022524/doc4.xml","form_type":"4"}},{"id":2307082,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Common Stock","published_at":"2022-04-04T21:08:54.000Z","date":"2022-03-31","kind":"exercise","acquired":true,"shares":36062,"price":1.89,"value":68157.18,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":304442,"source":{"system":"sec-edgar","filing":"0001209191-22-022524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919122022524/doc4.xml","form_type":"4"}},{"id":2387337,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-18T00:07:19.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":10.58,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-011031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919122011031/doc4.xml","form_type":"4"}},{"id":2471131,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Common Stock","published_at":"2021-12-15T22:21:43.000Z","date":"2021-12-14","kind":"purchase","acquired":true,"shares":4000,"price":11.6,"value":46400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":268380,"source":{"system":"sec-edgar","filing":"0001209191-21-069796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121069796/doc4.xml","form_type":"4"}},{"id":2471130,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Common Stock","published_at":"2021-12-15T22:21:43.000Z","date":"2021-12-13","kind":"purchase","acquired":true,"shares":4000,"price":12.12,"value":48480.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":264380,"source":{"system":"sec-edgar","filing":"0001209191-21-069796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121069796/doc4.xml","form_type":"4"}},{"id":2626901,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-22T22:07:07.000Z","date":"2021-07-20","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":95000,"derivative":{"exercise_price":31.23,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-21-047831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121047831/doc4.xml","form_type":"4"}},{"id":3020548,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67556,"kind":"person","name":"Combs Andrew","position":1,"cik":"0001825005","reported_name":"Combs Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of Chemistry"}}],"security":"Common Stock","published_at":"2020-09-30T00:11:04.000Z","date":"2020-09-29","kind":"purchase","acquired":true,"shares":1000,"price":19,"value":19000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":260380,"source":{"system":"sec-edgar","filing":"0001209191-20-052405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052405/doc4.xml","form_type":"4"}}]}